Risedronate for the prevention of hip fractures: concern about validity of trials.
Halbekath
Jutta Martha
JM
Schenk
Stefanie
S
von Maxen
Andreas
A
Meyer
Gabriele
G
Mühlhauser
Ingrid
I
D000368:Aged; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006620:Hip Fractures / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D015203:Reproducibility of Results; D012189:Retrospective Studies; D000068296:Risedronic Acid; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid